Search

Patheon's Puerto Rico Site Receives European Regulatory Approval

Source: Patheon Inc.
Website: www.patheon.com
RESEARCH TRIANGLE PARK, NC, Aug. 10 /CNW/ - Patheon Inc. (TSX: PTI), a
global provider of drug development and manufacturing services to the
international pharmaceutical industry, announced today that its Manati, Puerto
Rico solid dose manufacturing facility received regulatory approval from the
European Medicines Agency (EMEA) following the completion of a successful
inspection in May by the Medical Products Agency of Sweden.
The successful inspection of the Manati facility demonstrates Patheon's
strong commitment to quality and regulatory compliance. So far in 2009,
Patheon has successfully completed 19 regulatory inspections at 9
manufacturing sites, including 8 FDA inspections and 2 European inspections.
"Patheon's track record of regulatory compliance underscores our commitment to
quality and reliability for our customers. We are particularly pleased with
this recent result in Puerto Rico, as it represents the latest in a successful
number of recent inspections." says Terry Novak, President, Patheon North
America. "The approval of our Manati facility allows us to ship solid dosage
product into Europe from Puerto Rico, which provides additional benefit and
flexibility for our clients."
About Patheon Inc.
Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of
contract development and manufacturing services to the pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 pharmaceutical and biotechnology companies.
Patheon's services range from preclinical development through the commercial
manufacturing of a wide array of dosage forms including parenteral, solid,
semi-solid and liquids. Patheon's comprehensive range of fully integrated
Pharmaceutical Development Services includes pre-formulation, formulation,
analytical development, clinical supplies, scale-up and commercialization.
Patheon's ability to integrate development and manufacturing services ensures
that our customers' projects are delivered on time and meet the high standards
of quality that Patheon is known for.
Patheon's integrated development and manufacturing network of 10
facilities and 7 development centers, across North America and Europe, strives
to ensure that customer products can be launched timely and confidently
anywhere in the world.
Caution Concerning Forward-Looking Statements
This news release may contain forward-looking statements which reflect
management's expectations regarding the Company's future growth of operations,
performance (both operational and financial) and business prospects and
opportunities. These statements are made in the context of the risks and
uncertainties that are outlined in the Company's public documents, which can
be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.
%SEDAR: 00001700E